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ABSTRACT
Background. Extranodal spread (ENS) is an established
adverse prognostic factor in metastatic cutaneous squa-
mous cell carcinoma (cSCC); however, the clinical
signiﬁcance of soft tissue metastases (STM) is unknown.
The aim of this study was to evaluate the prognosis of
patients with STM from head and neck cSCC, and to
compare this with that of node metastases with and without
ENS.
Methods. Patients with cSCC metastatic to the parotid
and/or neck treated by primary surgical resection between
1987 and 2007 were included. Metastatic nodes[3c mi n
size were an exclusion criterion. A Cox proportional hazard
model was used to determine the effect of STM adjusting
for other relevant prognostic factors.
Results. The population included 164 patients with a
median follow-up of 26 months. There were 8 distant and
37 regional recurrences. There were 22 were cancer-spe-
ciﬁc deaths, and 29 patients died. STM was a signiﬁcant
predictor of reduced overall (hazard ratio 3.3; 95% conﬁ-
dence interval 1.6–6.4; P = 0.001) and disease-free
survival (hazard ratio 2.4; 95% conﬁdence interval 1.4–4.1;
P = 0.001) when compared to patients with node disease
with or without ENS. After adjusting for covariates, STM
and number of involved nodes were signiﬁcant independent
predictors of overall and disease-free survival.
Conclusions. In metastatic cSCC of the head and neck, the
presence of STM is an independent predictor of reduced
survival and is associated with a greater adverse effect than
ENS alone.
In countries with large white populations and high
ambient solar exposure such as Australia and New Zealand,
cutaneous squamous cell carcinoma (cSCC) is a major
public health problem.
1 Most cases of cSCC arise in the
head and neck, and regional metastases to parotid and/or
cervical lymph nodes are thought to occur in approxi-
mately 5% of patients, decreasing 5-year survival rates to
46–70%.
2–9
Although extension of metastatic squamous cell carci-
noma (SCC) beyond the lymph node capsule (extracapsular
spread or extranodal spread, ENS) is a well-established
adverse prognostic factor, there is no published evidence
regarding the clinical signiﬁcance of soft tissue metastases
(STM) in cSCC.
6,10 STM are deﬁned as free soft tissue
tumor deposits lacking continuity with the primary tumor
and without discernible associated lymph node tissue.
It remains unclear whether these are true extranodal
metastases or whether they represent lymph nodes replaced
by tumor to such an extent that the underlying node is
unrecognizable.
11 In the latter case, STM may represent an
advanced stage of node disease beyond ENS, and if this is
the case, larger tumor size and reduced locoregional con-
trol would be expected. This notion is supported by the
known correlation between the size of involved lymph
nodes and the presence of ENS.
12 Several studies of
mucosal head and neck SCC have demonstrated an asso-
ciation between STM and unfavorable outcomes,
comparable to the presence of ENS.
11–16
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STM were similar to node deposits with ENS or whether
they represented a distinct entity with more aggressive
tumor biology. The goal of the current study was to eval-
uate the prognostic signiﬁcance of STM in head and neck
cSCC, and to compare it with that of node metastases with
and without ENS.
MATERIALS AND METHODS
ClinicopathologicdatafrompatientstreatedattheSydney
Head and Neck Cancer Institute, Royal Prince Alfred Hos-
pital, Sydney, Australia, were recorded prospectively on a
computerized database since 1987. The database contains
information on patient demographics, clinical and patho-
logic staging, treatment details, histopathologic features,
duration of follow-up, and status at last visit. All patients
with cSCC metastatic to the parotid and/or neck treated by
primarysurgicalresectionwithcurativeintentbetween1987
and 2007 were identiﬁed. The pathology details recorded in
the database were cross-checked with the original pathology
reports and the database was updated where necessary.
Slides of tumors from all selected patients were reexamined
by a pathologist experienced in the examination of head and
neck tumors (R.M.).ENSwas deﬁned asextensionoflymph
node metastases of SCC beyond the nodal capsule, and
STMsweredeﬁnedasfreesofttissuetumordepositslacking
continuity with the primary tumor and without discernible
associated lymph node tissue. The presence, size, and
number of STM were measured and added to the existing
database. To exclude the effect of bulky tumors, only
patients with metastatic nodes B3 cm in size were included.
Data were collated and ﬁltered by Microsoft Excel, and
statistical analysis was performed by SPSS version 16.0
(SPSS, Chicago, IL). Categorical data were analyzed by
chi-square test or Fisher’s exact test, normally distributed
continuous data by t-test, and nonparametric data by
Kruskal–Wallis test where appropriate. All statistics were
two sided, and a P value of \0.05 was considered statis-
tically signiﬁcant. Overall survival was calculated from the
date of surgery to date of death or last follow-up. Disease-
free survival was calculated from the date of surgery to
date of last follow-up including date of death from any
cause if there were no recurrence or date of ﬁrst disease
recurrence. Differences in survival were determined by
univariate Cox regression analysis, and survival curves
were generated by the Kaplan–Meier method. A Cox pro-
portional hazard model was used to adjust for the effect of
other statistically signiﬁcant covariates and potential con-
founders, including postoperative radiotherapy and the
number of tumor deposits, by means of purposeful selec-
tion of covariates to develop a ﬁnal multivariable model
according to the method of Hosmer et al.
17
RESULTS
Study Population
The study population included 164 patients, 142 men
(86.6%) and 22 women (13.4%), with a median age at
surgery of 73 years (range 25–98 years) and a median
follow-up period of 26 months. Surgical treatment con-
sisted of parotidectomy with neck dissection in 129
patients (78.7%), neck dissection alone in 14 (8.5%), and
parotidectomy alone in 21 (12.8%). Adjuvant radiotherapy,
at a median dose of 54 Gy (range 32–66 Gy), was
administered to 131 patients (79.9%).
Pathology of Metastatic Disease
The median number of either positive nodes or meta-
static deposits was 1, while the mean number was 3.7
(range 1–68). Most patients (104, 63.4%) had only one
affected node or STM. The margins of excision were clear
in 83 patients (50.6%), involved in 27 patients (16.5%),
and close (\5 mm) in 38 patients (23.2%), and there was
no information on margin status in 16 patients (9.8%).
Fifty-eight patients (35.4%) had node metastases without
ENS or STM, 51 (31.1%) had ENS and STM, 33 (20.1%)
had ENS alone, and 22 (13.4%) had STM alone (Fig. 1).
The median size of the largest node or STM was 1.8 cm.
The mean diameter of involved nodes (in the selected
group of patients with tumors B3 cm) without ENS, nodes
with ENS, and STMs was 1.9 cm (range 0.5–3.0 cm),
1.7 cm (range 0.6–2.5 cm), and 2.1 cm (range 1.0–3.0
cm), respectively (P = 0.085; Kruskal–Wallis test). Sev-
enty-one patients (43%) had nodes\1.5 cm.
During the follow up there were eight distant and 37
regional recurrences. Twenty-nine patients died; there were
FIG. 1 STM of cutaneous SCC
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of reduced overall [hazard ratio (HR) 3.3; 95% conﬁdence
interval (CI) 1.6–6.4; P = 0.001] and disease-free survival
(HR, 2.4; 95% CI 1.4–4.1; P = 0.001) when compared to
patients with node disease with or without ENS (Fig. 2).
The presence of ENS was also a signiﬁcant predictor of
survival when compared to patients without ENS or soft
tissue deposits. Other signiﬁcant predictors of survival on
univariate analysis are summarized in Table 1. After
adjusting for other covariates, STM and number of
involved nodes (or tumor deposits) were signiﬁcant inde-
pendent predictors of overall and disease-free survival, but
ENS was not (Table 2).
To compare the prognostic impact of STM and ENS, the
study population was divided into four groups: STM and
ENS; STM alone; ENS alone; and node disease without
ENS or STM. The adjusted Cox regression curves in Fig. 3
show that the worst outcomes were associated with STM
with or without associated ENS, while node disease with-
out STM or ENS was associated with the most favorable
outcomes, and ENS alone had an intermediate prognosis.
When the subset of patients with STM alone (n = 22)
were compared with those with ENS alone (n = 33),
patients with STM alone had signiﬁcantly reduced overall
survival (HR 4.1; 95% CI 1.0–16.8; P = 0.048) when
compared to those with ENS alone after adjusting for the
effect of age and number of lymph nodes (Fig. 4).
DISCUSSION
The results of the present study suggest that the presence
of STMs is associated with a worse prognosis than the
presence of node metastases (with or without ENS). We
were unable to conﬁrm that ENS in node metastases B3c m
in size is associated with reduced survival after adjusting
for the effect of STM and number of nodes involved.
However, it is likely that the study is insufﬁciently powered
to detect a statistically signiﬁcant difference because the
adverse effect of ENS was considerably less than that of
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TABLE 1 Univariate survival analysis
Variable HR 95% CI P value
Overall survival
Age (continuous) 1.04 1.00–1.08 0.031
Involved margin 1.62 0.73–3.56 0.233
Maximal lesion size
Size (continuous) 1.02 0.96–1.09 0.484
[1.5 versus B1.5 cm 1.28 0.56–2.92 0.565
No. of nodes
2–3 nodes versus 1 node 1.03 0.38–2.83 0.949
C4 nodes versus 1 node 5.13 2.35–11.20 \0.001
STM 3.25 1.63–6.49 0.001
ENS
a 2.59 1.30–5.16 0.007
Adjuvant radiotherapy
a 0.72 0.33–1.57 0.405
Disease-free survival
Age 1.02 0.99–1.04 0.220
Involved margin 2.18 1.20–3.96 0.010
Maximal lesion size
Size (continuous) 1.02 0.98–1.07 0.390
[1.5 versus B1.5 cm 1.40 0.73–2.67 0.310
No. of nodes
2–3 nodes versus 1 node 1.73 0.84–3.57 0.135
C4 nodes versus 1 node 4.94 2.51–9.73 \0.001
STM
a 2.42 1.42–4.14 0.001
ENS
a 2.01 1.17–3.45 0.012
Adjuvant radiotherapy 0.79 0.42–1.50 0.471
a Different reference categories for STM and ENS mean hazards are
not comparable
276 W. Kelder et al.STM (type II error). This lends support to the argument that
STMs, rather than representing lymph nodes completely
replaced by tumor, may instead represent a distinct bio-
logic entity (namely deposits of tumor in soft tissue, not
associated with lymph nodes).
Because number and size of tumor deposits are impor-
tant prognostic factors and size of the tumor is related to
the presence of ENS and STM, we tried to exclude the
effect of bulky tumors by only selecting patients with
tumors up to 3 cm as supported by the N1S3 and current
tumor, node, metastasis staging systems.
10,12,18 In this
subgroup, the presence of STM was a statistically signiﬁ-
cant adverse prognostic factor, and the effect was even
more pronounced in patients with both STM and ENS.
A limitation of this study is that primary tumor infor-
mation is not evaluated. Other factors that could confound
the effect of STM include perineural invasion, lympho-
vascular invasion, depth of invasion, tumor grade, and
immune status of the patient.
3,7 Many of these factors were
adopted in the 7th edition of the American Joint Committee
on Cancer/International Union Against Cancer staging
system for cSCC. The prognostic signiﬁcance of primary
tumor factors in patients with node metastases is unknown.
Patients in this study were only referred with node
metastases, primary tumor data was often unavailable and
many patients have either no identiﬁable primary or mul-
tiple potential primaries.
Extranodal spread and soft tissue metastases are com-
mon ﬁndings in patients with metastatic cutaneous and
mucosal SCC, one or the other being present in most
patients.
6,
11–16 Generally, the distinction has been ignored
by pathologists and clinicians and both have been grouped
together. Studies in mucosal SCC have shown that the
presence of both STM and/or ENS is related to reduced
survival, but it is not clear from those studies whether STM
and ENS are identical.
11–16 Partly this is because the term
‘‘soft tissue deposit or metastasis’’ is used rather impre-
cisely and may include direct extension of tumor cells from
the primary site or even ENS of tumor from the lymph
node into the soft tissues of the neck. In an attempt to be
more speciﬁc we deﬁned STM as ‘‘free soft tissue tumor
deposits lacking continuity with the primary tumor and
without discernible associated lymph node tissue.’’ In
melanoma, ‘‘microscopic satellitosis’’ represents a parallel
adverse prognostic factor that has been more extensively
studied and strictly deﬁned as ‘‘any discontinuous nest of
metastatic cells more than 0.05 mm in diameter that are
clearly separated by normal dermis from the main invasive
component of melanoma by a distance of at least
0.3 mm.’’
19 Despite the similarity, we believe that these are
different biologic entities as STM mainly occur in node
basins rather than as dermal deposits within close prox-
imity to the primary tumor. Regardless, a strict deﬁnition
such as that adopted for microscopic satellitosis would
enable reliable and reproducible estimates of STM’s
prognostic signiﬁcance in future studies.
20–22
STM could occur via spread of tumor cells through
lymphatic channels draining the primary tumor or through
perineural or vascular routes. Tumor cells that spread
through lymphatics eventually reach lymph nodes, where
they will either be contained by the local immune system
or will overcome the local host defense and may eventually
replace the whole lymph node with tumor. It has been
demonstrated in animal models that some tumor cells
escape the lymphatics or travel through small vessels and
end up as free tumor deposits in the soft tissues.
23 Tumors
escaping lymphatic channels may possess cellular proper-
ties that promote growth and dissemination and may avoid
some of the immune regulation that normally occurs in
lymph nodes, whereas tumors with direct vascular invasion
may be more prone to distant spread. The real explanation
is likely to be complicated and multifactorial, and merits
further study.
In this series, the predominant site of recurrence was
within the parotid and neck suggesting that the focus of
treatment should remain on optimizing locoregional con-
trol. There is good evidence that combined modality
treatment with surgery and adjuvant radiotherapy improves
locoregional control and survival in head and neck
cSCC.
5,24–26 However, radiotherapy is associated with
marked acute and long-term toxicity, and a recent multi-
center study involving our institution suggests there is a
low-risk group of patients with N1S3 stage I disease (single
lymph node B3 cm) and no ENS or STM that may be
suitable for treatment with surgery alone.
10,27,28 Con-
versely, the results of the Trans-Tasman Radiation
Oncology Group trial (Postoperative Skin Trial 05.01;
http://www.trog.com.au/) are awaited to determine whether
TABLE 2 Final multivariable survival analysis models
Variable HR 95% CI P value
Overall survival
Age (continuous) 1.03 1.00–1.07 0.072
No. of nodes 2.34 1.49–3.66 \0.001
STM 2.91 1.44–5.88 0.003
Adjuvant radiotherapy 0.63 0.28–1.40 0.256
ENS 1.54 0.72–3.29 0.263
Disease-free survival
Age 1.01 0.98–1.04 0.487
Margin 0.96 0.49–1.86 0.899
No. of nodes 2.31 1.61–3.32 \0.001
STM 2.35 1.35–4.07 0.002
Adjuvant radiotherapy 0.75 0.39–1.44 0.385
ENS 1.30 (0.71–2.38) 0.395
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moradiation may be beneﬁcial for high-risk metastatic
cSCC of the head and neck. Hence, accurate prognostic
information remains critical to making decisions regarding
deescalation or intensiﬁcation of adjuvant therapy.
Soft tissue metastases have a comparable adverse effect
on survival to multiple lymph node metastases. Therefore,
adjuvant radiotherapy should be administered to all
patients with STM, even if the metastasis is a small single
deposit. We are cautious about making recommendations
for patients with ENS, despite being unable to demonstrate
a marked effect. Therefore, conventional multimodal
therapy should be considered standard on the basis of
evidence from multiple studies which have shown ENS to
be an adverse prognostic factor, even though they are likely
to have grouped ENS and STM together.
6,7,10
The pathologic examination and reporting of parotid and
neck dissection specimens is paramount to obtaining
reliable prognostic information on which to base treatment
decisions. It is essential that examination of all tumor
deposits and lymph nodes (including the smallest nodes) is
performed for the presence of ENS and STM, along with
measurement of the size and number of metastases.
10 This
approach has also been recommended in other solid
tumors, for example colorectal cancers, in which the
majority of metastases are found in lymph nodes that are
smaller than 5 mm in size, and even small metastatic tumor
deposits have a negative prognostic impact.
29–31 As in
many solid tumors, a low number of examined nodes
probably represents understaging, and is associated with
poorer prognosis.
31 Clearly, adequate staging requires not
only a meticulous surgical technique but also a detailed
pathologic evaluation.
In conclusion, in metastatic cSCC of the head and neck,
the presence of STM (with or without associated ENS) is a
statistically signiﬁcant independent predictor of reduced
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278 W. Kelder et al.survival and is associated with more unfavorable outcomes
than the presence of ENS alone. Further work is required to
determine the biologic mechanisms underlying this ﬁnding.
Similar to the guidelines in melanoma, pathology reports of
head and neck cSCC should include the number and size of
affected nodes,the presence ofENS,aswell asthe presence,
number, and size of STMs. The threshold for aggressive
multimodaltreatmentshouldbelowinthepresenceofSTM.
ACKNOWLEDGMENT W.K. was supported as a clinical and
research fellow by the Dutch Cancer Society (grant RUG 2008-4382).
OPEN ACCESS This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
REFERENCES
1. Staples M, Marks R, Giles G. Trends in the incidence of non-
melanocytic skin cancer (NMSC) treated in Australia, 1985–
1995: are primary prevention programs starting to have an effect?
Int J Cancer. 1998;78:144–8.
2. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl
J Med. 2001;344:975–983.
3. Brantsch KD, Meisner C, Schonﬁsch B, et al. Analysis of risk
factors determining prognosis of cutaneous squamous-cell car-
cinoma: a prospective study. Lancet Oncol. 2008;9:713–20.
4. Czarnecki D, Staples M, Mar A, Giles G, Meehan C. Metastases
from squamous cell carcinoma of the skin in southern Australia.
Dermatology. 1994;189:52–4.
5. Jol JA, van Velthuysen ML, Hilgers FJ, Keus RB, Neering H,
Balm AJ. Treatment results of regional metastasis from cutaneous
head and neck squamous cell carcinoma. Eur J Surg Oncol.
2003;29:81–6.
6. Oddone N, Morgan GJ, Palme CE, et al. Metastatic cutaneous
squamous cell carcinoma of the head and neck: the Immuno-
suppression, Treatment, Extranodal Spread, and Margin Status
(ITEM) prognostic score to predict outcome and the need to
improve survival. Cancer. 2009;115:1883–91.
7. Veness MJ, Palme CE, Morgan GJ. High-risk cutaneous squa-
mous cell carcinoma of the head and neck: results from 266
treated patients with metastatic lymph node disease. Cancer.
2006;106:2389–96.
8. Taylor BW, Brant TA, Mendenhall NP, et al. Carcinoma of the
skin metastatic to parotid area lymph nodes. Head Neck. 1991;
13:427–33.
9. O’Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS. Inci-
dence of cervical node involvement in metastatic cutaneous
malignancyinvolvingtheparotidgland.HeadNeck.2001;23:744–8.
10. Forest VI, Clark JJ, Veness MJ, Milross C. N1S3: a revised
staging system for head and neck cutaneous squamous cell car-
cinoma with lymph node metastases: results of 2 Australian
cancer centers. Cancer. 2010;116:1298–304.
11. Jose J, Moor JW, Coatesworth AP, Johnston C, MacLennan K.
Soft tissue deposits in neck dissections of patients with head and
neck squamous cell carcinoma: prospective analysis of preva-
lence, survival, and its implications. Arch Otolaryngol Head Neck
Surg. 2004;130:157–60.
12. Puri SK, Fan CY, Hanna E. Signiﬁcance of extracapsular lymph
node metastases in patients with head and neck squamous cell
carcinoma. Curr Opin Otolaryngol Head Neck Surg. 2003;
11:119–23.
13. MacLennan K, Jose J, Ferlito A, et al. Cervical soft tissue
metastases in head and neck cancer. Acta Otolaryngol. 2003;
123:336–9.
14. Coatesworth AP, MacLennan K. Squamous cell carcinoma of the
upper aerodigestive tract: the prevalence of microscopic extra-
capsular spread and soft tissue deposits in the clinically N0 neck.
Head Neck. 2002;24:258–61.
15. Violaris NS, O’Neil D, Helliwell TR, Caslin AW, Roland NJ,
Jones AS. Soft tissue cervical metastases of squamous carcinoma
of the head and neck. Clin Otolaryngol. 1994;19:394–9.
16. Shah JP, Cendon RA, Farr HW, Strong EW. Carcinoma of the
oral cavity. Factors affecting treatment failure at the primary site
and neck. Am J Surg. 1976;132:504–7.
17. Hosmer D, Lemeshow S, May S. Applied survival analysis:
regression modeling of time-to-event data. 2nd ed. Hoboken:
Wiley; 2008.
18. American Joint Committee on Cancer. Cancer staging handbook:
TNM classiﬁcation of malignant tumors. New York: Springer;
2002.
19. Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009
AJCC melanoma staging and classiﬁcation. J Clin Oncol. 2009;
27:6199–206.
20. Kimsey TF, Cohen T, Patel A, Busam KJ, Brady MS. Microscopic
satellitosis in patients with primary cutaneous melanoma: implica-
tions for nodal basin staging. Ann Surg Oncol. 2009;16:1176–83.
21. Balch CM. Microscopic satellites around a primary melanoma:
another piece of the puzzle in melanoma staging. Ann Surg
Oncol. 2009;16:1092–4.
22. Rao UN, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM.
Implications of microscopic satellites of the primary and extra-
capsular lymph node spread in patients with high-risk melanoma:
pathologic corollary of Eastern Cooperative Oncology Group
Trial E1690. J Clin Oncol. 2002;20:2053–7.
23. Cabanillas R, Secades P, Rodrigo JP, Astudillo A, Sua ´rez C,
Chiara MD. Orthotopic murine model of head and neck squa-
mous cell carcinoma. Acta Otorrinolaringol Esp. 2005;56:89–95.
24. Shimm DS, Wilder RB. Radiation therapy for squamous cell
carcinoma of the skin. Am J Clin Oncol. 1991;14:383–6.
25. Veness MJ, Palme CE, Smith M, Cakir B, Morgan GJ, Kalnins I.
Cutaneous head and neck squamous cell carcinoma metastatic to
cervical lymph nodes (nonparotid): a better outcome with surgery
and adjuvant radiotherapy. Laryngoscope. 2003;113:1827–33.
26. Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and
adjuvant radiotherapy in patients with cutaneous head and neck
squamous cell carcinoma metastatic to lymph nodes: combined
treatment should be considered best practice. Laryngoscope.
2005;115:870–5.
27. August M, Wang J, Plante D, Wang CC. Complications associ-
ated with therapeutic neck radiation. J Oral Maxillofac Surg.
1996;54:1409–15.
28. Ebrahimi A, Clark JR, Lorincz BB, Milross CG, Veness MJ. Met-
astaticheadandneckcutaneoussquamouscellcarcinoma:deﬁninga
low-risk patient. Head Neck.2 0 1 1 .d o i : 10.1002/hed.21743.
29. Haboubi NY, Abdalla SA, Amini S, et al. The novel combination
of fat clearance and immunohistochemistry improves prediction
of the outcome of patients with colorectal carcinomas: a pre-
liminary study. Int J Colorectal Dis. 1998;13:99–102.
30. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al.
Micrometastases and survival in stage II colorectal cancer. N
Engl J Med. 1998;339:223–8.
31. Jestin P, Pahlman L, Glimelius B, Gunnarsson U. Cancer staging
and survival in colon cancer is dependent on the quality of the
pathologists’ specimen examination. Eur J Cancer. 2005;41:
2071–8.
Carcinoma with Regional Metastases 279